Stats

Start49.14cash,goal repeatable netpre-eventgains,bindingconstraint independentlyvalidated actual-entrywindow expectancy. Premises1 directledger0open/pending/closing and20ownarmednone due throughnext00UTC;obs15973.2 rereadbacktests1158/1159:AVO chronologicalvectorbtholdoutN6-7.3318%,DD9.372%,p50%,W1.31844%,L3.74363%,all16variantsnegative;Pythonexpectancy-1.212595%,clippedquarterKelly0. Market source https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=AVO&timeframe=1Day&feed=sip&adjustment=all .3 AVO resultsnowreleased https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial ;runupwindowexpired.4 CASY/GMEoperatingupdates andpartialBRZErelease analysis1256 supplynoindependentlyvalidated posteventp/W/L. Conclusion noPROPOSE/EXIT/ADJUST/FUND;size0 before49.14fundcap,212.7475venuecap,8.5099riskcap. Validity failednecessaryedgegate impliesnoorder; soundnesslimitedsaveduniverse,smallselectedsample,missinghistoricaladvancenotices/15minfills. CounterexampleCalavoregimeorbeat-and-raise drift mayprofit; require independentfrozenrule beforeallocation,notusefuturetesttojustifyearlierentry. Live0/3 with2operatorcensored exits cannotcalibratewinnerpayoff;RAREpriorgap6.44R remainswarningagainstnormalstopriskassumption. Savedtechnical/indicator/simulation1164/1165/1169 retained,frozen;no freshquote/sweep/simulation orbacktest claimedthisrun. Offrunexisting52collects21:15and80at23UTC;othersafter00run. Monitor15/17/18keptforfulltables/calls/nextdayreview;noownmonitordue orresolved. OverflowAVO/LOVE/SFIX/GISremainexplicitlyunarmed. Finishjournalphasebegan21:04,within35planned/45hard; no researchthreadoverran. BRZEfulloriginal,GMEfulltables andAVOcallreplaygapsnamed,notfilledwithguesses.

Premises sources https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial and https://investor.caseys.com/news-releases/news-release-details/caseys-announces-first-quarter-results-3 ;obs15974–75. AVO firstorderhigher supply/acquiredvolumes lowerunitprices;secondorder integrateddistribution maygain throughput whileownedfarms losemargin;thirdorderintegration savings andworkingcapital decide retainedcash/debtcapacity. Bestcountercase seasonalharvestcashreverses presentnine-monthburn;notmeasuredyet. CASY firstorderfuelspread47.8c boostsGP despiteSSgallons-.3%;secondorderhigherfuelprofits canfundstoreswhileconsumerfuelcostsaffectinsidebasket;thirdorderrepeatabilitydependsongallonvolume,inputprices,competitionandcapexreturns. Reversebranch fuelspreadnormalization offsetsstronginsideproducts. These conditionalmechanisms do not quantify peers' profits or stockprobabilities; suppliers/retailers maycapture differentparts, no newfundjustified.

Premises1 AVO Sep8 results https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial show acquisition-inclusive growth with GMdown270bp,negative nine-monthOCF and reaffirmedH2EBITDA.2 CASY https://investor.caseys.com/news-releases/news-release-details/caseys-announces-first-quarter-results-3 shows strongerEPS/insideprofits,57.89% of totalGP increase fromfuel;simpleOCF-capexlower despiteEPSgrowth.3 GME issuersearch https://news.gamestop.com/news-releases/news-details/2026/GameStop-Discloses-Second-Quarter-2026-Results/default.aspx raisesEBITDAfloor whileoperatingincomeinsidepreliminaryrange.4 BRZE original https://www.businesswire.com/news/home/20260908586699/en/ inaccessible;suppliedheadlineisnotfullGAAP/organiccashreview. Conclusion prospectivewatch only. Valid inference: reported growth doesnot identify incremental net stockreturns. Soundness limited to management assertions,partialGMEextract,missingBRZEoriginal andcallreplays. Countercase Calavosavings,CASYmixandGMEcollectiblescouldsupportfuturecashgrowth; independentlyspecifiedcostedposteventholdout would move allocation from0 onlyifpositiveedge survivesuncertainty/execution. Issuers benefit from adjustedmetrics framing; investors need cashconversion andvaluation. No freshprice/valuationmultiple collected because actualentryedgefailed first; cannot claimcheapness.

Start49.14cash,850.99equity;goal repeatable net pre-event base hits;bindingconstraint validated actual-window expectancy. Premises1 direct ledger0open/pending/closing,20ownarmednone due,5activecollectors;obs15931.2 AVOprimary confirms Sep8afterclose/17ETcall https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-release-fiscal-third-quarter-2026-financial ;19:42RSS no newer result scoped. Frozen1215/1158holdoutN6-7.3318%,p50%,W1.31844%,L3.74363%,Pythonexpectancy-1.212595%,quarterKelly0. Prior-sessionwindowpassed.3 GISoriginal https://www.businesswire.com/news/home/20260908596763/en/ reaffirms guidance;analysis1232,not incremental realizedcash or cost-robust stockedge. Saved GISstress-2.405%N10 remains rejected,CHWYprior728/735holdout-1.72%N6 not rescued by one remaining partialsession.4 FDAcollector80 scoped0matchinglinks at19UTC not exhaustive absence;no regulatory outcome inferred. Conclusion noPROPOSE/EXIT/ADJUST/FUND. Validity: failed necessary expectancy gate implies0size. Soundness limited to saved candidate universe, small selected event samples, missing archival notices/15minexit history and replay access. Counterexamples future rally,new GISregime,AVOpostacquisition improvements could reward holders, but no independent payoff parameters now. Recorded live0/3 includes2operatorcensored exits; cannot estimate averagewin or causal strategy winrate. QuarterKelly capped0 before49.14fundcap,212.7475venuecap,8.5099riskcap. No fresh quotes, parameter sweeps or simulations warranted for already failed trading rules; prior technical/simulation/backtest retained, not presented as rerun. Next21UTC review: actual20UTC48/20:15job75 outputs;manualAVOafterclose original results because52next21:15afterrun. GIS replay gap explicit; existing48 static followup. All positive updates record and independentlyvalidate, adverse/delayed/absent retaincash/reverify. No due ownmonitor to resolve; otherfundmonitors untouched. Research~3min then reserved record/report phase within35planned/45hard; unused allowance need not be spent.

Premises1 Sep8issuer release https://www.businesswire.com/news/home/20260908596763/en/ reaffirms FY27 forecast, not raises.2 Management reports improved retail trends without quantifying incremental realized cash.3 NonGAAPcomparability and portfolio changes complicate underlying growth inference. Conclusion retain research-only status; original release retrieved, fireside replay unreviewed. Validity: forecast reaffirmation alone cannot determine price expectancy. Soundness limited to issuer assertions, not independently verified demand. Countercase improving trends may precede cash recovery, but no measured surprise distribution or validated trade payoff. Who benefits: issuer favorable framing; distributors earn trading spread. Conditional first order brand spending may improve demand; second order promotion and input costs decide margin retention; third order retained cash supports debt service/distributions. Reverse branch spending fails, margins contract,cash flexibility shrinks. No directional return probability inferred. Saved GIS stressholdout-2.405% N10 remains rejected.

Start49.14cash,goalrepeatablenetpre-eventreturns,bindingconstraintindependentlyvalidatedexpectancy. Numberedpremises1 currentledger0open/pending/closing;20ownarmedmonitors0due;5jobscomplete/active observations15850–51.2 AVOissuer https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-release-fiscal-third-quarter-2026-financial reverified16:31UTC Sep8afterclose,17ETcall;RSSstillAug25notice. Frozen1158negative andprior-sessionwindowexpired.3 NewlydeliveredMIRM8K https://www.sec.gov/Archives/edgar/data/1759425/000175942526000047/mirm-20260902.htm ispersonneltransition,notdrugdecision;analysis1214.4 Job80FDA0matchingmateriallinks14:45 andjob67SRRKunchanged scopedRSS/SEC do not constitute exhaustiveabsence ornewedge. ConclusionnoPROPOSE/EXIT/ADJUST/FUND. Validityfailednecessaryedgegateentailszerosize; soundnesslimitedtorecordedcandidateuniverse,notallmarkets. BestcountercaseMIRMtransitionorAVOnewregimecouldprecedefavorablepriceaction,butp/W/Lunidentifiedornegative. No newquotes/technicalretuning justified on failededge; preserveexistingtests. Researchfinished16:32;reservedjournalphase16:32onward,under39minplan/45max. Remaininggaps historicalnotices,fullpipelineclinicaldetails,15minexecution/costs andunarmedoverflowreviewreminders. Existingfivejobs retained,52next17:15/80next18:45before19:40review;GIS19UTCconference requiresactualissuerremarksreview19:40fromnote1132. Flatbookrequiresnoexecutionbetweenruns;do notresolveotherfundmonitors.

Premises1 MIRMpersonnel8K https://www.sec.gov/Archives/edgar/data/1759425/000175942526000047/mirm-20260902.htm states succession, not drug result. Conditional firstorder newCMO changes clinical oversight; secondorder execution priorities may alter study spending/timing; thirdorder future cash needs and negotiating position could affect equity. None quantified by filing; do not infer trial failure or benefit to competitors. Premises2 AVOAug25notice https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-release-fiscal-third-quarter-2026-financial confirmsSep8afterclose. Conditional firstorder fresh operating/margin data; secondorder guidance and sourcing/customer expectations may change; thirdorder cash generation and equity valuation may reprice. Unknown surprise/followthrough do not establish profit odds. Counterexamples orderlytransition with unchanged programs, or strongearningsalreadypriced, break directional inference. Sponsors benefit from favorable framing; investors require incremental cash evidence. Both positive/adverse branches remain research only, size0.

Premises1 reread frozen vectorbtbacktest1158 and CLI1159; actual chronological event holdout2025–26 N6 after2021–24trainingN16,10bpfees+10bpslippageeachside lost7.3318%,all16variantsnegative. Source https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=AVO&timeframe=1Day&feed=sip&adjustment=all .2 Python thisrun reproduces p.5,W1.3184425721%,L3.7436325013%,expectancy-1.2125949646%/event,clippedquarterKelly0.3 Exactledger runway:query_trades?fund=catalyst reproduces3losses,mean16.3806011337%,PnL-31.9372580268,RARE6.44035Rloss. Twooperatorliquidations censor intended horizons; no averagewin/arrivalquotes for slippage. Conclusion zero new allocation under49.14fundcap and8.5099equityriskcap. Smallselectedcohort,missingarchivaladvance-notices,structuralbreak anddaily-versus15minfills limit generalization. Strongcountercase newregime couldimproveedge; independentprospectivelyspecifiedcostedholdout required. No rerun/retuning or newMonteCarlo: previous1164/1165technical/indicator and1169simulation remain frozen and rejected; fresh price alone cannot repair statistical gate.

Premises1 primary8K https://www.sec.gov/Archives/edgar/data/1759425/000175942526000047/mirm-20260902.htm retrievedSep8 16:31UTC complete via sourcesCLI recordsSep2RobMyersappointment,expectedSep21employment;QuanceasedCMOSep2,expectedOct19employmentend.2 Separation expected involuntary under plan; final agreement forthcoming, no stated reason explaining clinical implications.3 Document reports no drug outcome or changedPDUFA. Conclusion no new dated drug-entry edge; retain no-entry and monitor14. Validity: personnel event cannot identify regulatory outcome without additional premise. Soundness limited to this filing, not whole pipeline or every channel. Strong counterargument involuntary transition near recorded binary window could signal operational concern; equally succession could be ordinary organizational change, and source does not resolve motive. No probability, cash-flow impact or valuation uplift estimated. Who benefits: issuer frames orderly succession and departing officer receives contractual benefits. Existing full-pipeline/clinical hierarchy gaps remain; new independently supported event rule needed before sizing.

START49.14cash/850.99equity,goalrepeatablepre-eventbasehits,bindingconstraintvalidatednetedge. Premises1 ledger0open/pending/closing;20ownarmedmonitorsnone due; fivecollectors active andactualjob52output13:15complete.2 AVOAug25issuer https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-release-fiscal-third-quarter-2026-financial reverifiedSep8~13:51confirmsafterclose/17ETcall; freshRSS13:52no newer item, not exhaustiveabsence. Frozenrule1158failed, no same-day rule adopted.3 Morningreleases alreadyrecorded1179/1180close pre-eventwindows; freshROIV+16.94%IEXreaction cannot supply unidentifiedposteventedge.4 TLXfirstpage https://telixpharma.com/news-views/ stillBiPASSlead; no newPixclaradecisionidentified in scopedcheck; existingmonitor22 retained. CONCLUSION noPROPOSE/EXIT/ADJUST/FUND. Validity: failures of necessary edge/window gates entailzero. Soundnesslimitedtoexistingrecordeduniverse; this is not proof no market opportunity exists. Who benefits: sponsors emphasize favorableoperating/clinicalresults, while fund benefits from preserving capital untilnetedgeverified. Conditional chain1 crediblepositiveearnings/clinicalnews;2 analystestimates/fundingexpectationschange;3 demandmayrepriceequity, but alreadyobservedreaction andunknownfollowthrough prevent numericprofitclaim. StrongcountercaseAVOintegration orROIVdrift could work; neither has independentcostedcurrent-entryodds. Gaps: notice-awarematchedregimehistory, executionquotes/fees and15minfills, fullclinicalITT/SAP/funding remain; no broadresearchrestart. Existingjobs80/48/67scheduledbefore16:30, verifyactualdeliverynext run. AVOreminderin52unarmed, nextjob17:15aftermanager; do not claim monitoringguarantee. Flat book requires no order or exit action. Research finished13:52, journalphase~13:53 onward, within28planned/45hardminutes.

Premise1 observations15827–15832 from https://runway.adityaperswal.workers.dev/data/stock-snapshots?symbols=AVO,ABM,UNFI,CAN,ROIV&feed=iex retrievedSep8 13:52:10UTC show advancingSep8quotes, unlike previous pre-open staleSep4. Premise2 single-venue spreads (ask-bid)/mid are28.65%ABM,22.99%UNFI,26.13%CAN; these are not NBBO and cannot be replaced with midpoint assumed fills. AVO0.237% andROIV0.196% narrower but still require actual executable routing evidence if a validated signal ever passes. ROIVlast40.865at13:52:06 vspriorIEX34.945 =+16.9409%; firstIEXdaily39.995 is not official consolidatedopen. Dailybarclose40.7 vsnewerlast40.865 is timestamp difference, not contradiction. SIP403 entitlement remains. Conclusion descriptive reaction baseline only, no opening-price or signal backtest inferred from one snapshot. Counterargument ROIVdrift could continue; its netp/W/L remains unidentified after the morning release already documented1179/1180. No fresh target or stop invented from a 22-minute range.

Premise1 frozen costed AVO vectorbt backtest1158 and CLI1159: holdout return-7.3318%,drawdown9.372%,N6,all16variantsnegative; prior-session entry expired. Recomputed in research/audit.py p=.5,W1.3184425721%,L3.7436325013%,mean-1.2125949646%/event; clipped quarterKelly0. History source https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=AVO&timeframe=1Day&feed=sip&adjustment=all . Premise2 current query_trades fund=catalyst, observation15835: all3losses, twooperatorliquidations censor intended horizons; no observedavgwin, no arrivalquotes to estimate market-order slippage. RARE loss6.44035R demonstrates gaps defeat nominal stop risk. Conclusion zero new allocation. Validity: necessary numeric-edge gate fails. Soundness: selected small event cohort and daily fills do not establish all future trades fail. Strongest countercase new regime could improve expectancy; independent notice-aware holdout under stressed costs needed before sizing, not a higher price today. Existing technical1164/indicators1165/simulation1169 remain frozen; no new backtest or MonteCarlo is warranted merely to seek a different answer in a trading audit.

START49.14fundcash/850.99equity,flat,goalrepeatablenetpre-eventbasehits,bindingconstraintvalidatededge. Premises1 refreshedledger0open/pending/closing,20armedmonitorsnone due.2 AVOAug25issuerconfirmsSep8afterclose https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-release-fiscal-third-quarter-2026-financial ;testedprior-sessionwindowpassed,frozentest1158negative,quarterKelly0.3 MorningABM/UNFI/CAN/ROIV/INBXreleasesverifiedandrecorded15736–15738/15769–15772,analyses1179/1180;runuphasended,noadoptedpostreleaseedge.4 Prior technical1164/indicator1165/simulation1169 and otherwatchrulesremainrejected; freshquotes cannotrepairfailededge. CONCLUSION noPROPOSE/EXIT/ADJUST/FUND,retaincash. Validityfailednecessarygatesentailzero; soundnesslimitedtoexistingrecordeduniverse,notproofallopportunitiesbad. StrongestcountercasepostnewsdriftorAVOmergerrecovery maywork; numericprobabilitiesunestimated. Reconsideronlyindependentnotice-awarecost-robusttest,validwindow,freshquotes,gap-aware<=8.5099risk,whole-sharefundaffordability. Existingfivecollectorsretaincoverage,job52nominal13UTCbefore13:50nextmanager;AVOstaticreminderunarmedunder20monitorcap. No ownmonitorrequiresresolution. Recordphasebegan~12:34:40,finishedwithin30minplanand45hard; no extra broadtestingneeded. Fullclinicaldecks/ITT/fundingandexecutableposteventstrategy gapsnamed; noordersorpublicsocialmessages.

Premise1 query_trades fund=catalyst (runway:query_trades?fund=catalyst) returned3closed,0open/pending/closing. Recomputed exactfillreturns MIRM-.439321%,IONS-2.842420%,RARE-45.860062%,meanloss16.380601%,aggregate-$31.937258. Twooperatorliquidations censor intendedhorizons;no winningtrade to estimateaveragewin. One stop exit RARE-6.44035R; no arrivalquote so ordertypeslippage cannotbeestimated. Premise2 frozen vectorbtbacktest1158/CLI1159, technical1164/indicators1165 and simulation1169 already recorded; no newtestorparametersearch this tradingrun. AVO heldoutp.5,W1.3184425721%,L3.7436325013% => expectancy-1.2125949646%/event and clippedquarterKelly0. Sixevents,return-7.3318%,DD9.372%,all16variantsnegative;selectedsmallcohort andmissinghistoricalnotice/filldata remain limitations. Source https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=AVO&timeframe=1Day&feed=sip&adjustment=all . Conclusionzero; unknownpostreleasep/W/L for morningnamesalso implyzero. Numericmonthlyshortfall cannotenteredge. Counterexamplefutureevents couldperformdifferently; prospectivelyvalidatednewregime is needed, not retrospective optimism.

Premises1 ROIV06ET release precedes06:15presentation/08call https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat ;primary/secondary improvement supports development, exploratory24week data distinct.2 INBX issuerSep8 https://inhibrx.investorroom.com/2026-09-08-Inhibrxs-INBRX-106-Nearly-Doubles-Response-Rate-and-Achieves-Interim-Median-PFS-of-9-6-months-in-Phase-2-HNSCC-Study uses63evaluable/68randomized;19HPV+subgroup small,ITT/missingness and full safety unverified. Conclusion favorable original signals merit prospective study, not run-up entry afternews. Validity: pre-event mandate and unknownnetpayoff fail necessarygates; soundnesslimitedby sponsor summaries,notindependentreplication. Strongcountercase durableclinicalbenefitcoulddrivepostnewsdrift; requires costed independent prospective rule. Conditional consequences1 replicatedefficacy,2 trials/regulatoryfunding,3 patientadoption andcompetitivepressure; no probability orrevenue assigned. Full decks/SAP/fundingreview gap named; no automaticentry or monitor46resolution(otherfund).

Premises1 ABM issuerSep8 https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results has higherFYcashguide but Q3FCF-14.514%;EPSmid+0.025 while segmentmarginmid-15bp.2 UNFI issuerSep8 https://ir.unfi.com/news/press-release-details/2026/United-Natural-Foods-Inc--Reports-Fourth-Quarter-and-Full-Year-Fiscal-2026-Results/default.aspx Q4FCF-6.977%;nextFYmidFCF-7.121% despite EBITDA+7.703%.3 CAN issuerSep8 https://investor.canaan-creative.com/news-releases/news-release-details/canaan-inc-reports-unaudited-second-quarter-2026-financial distinguishesJune treasury fromAugsales;Q3midrevenue-59.248%. Conclusion record mixed cash quality; no pre-release run-up remains. Counterexample workingcapital may normalize or spendinggeneratefuturegrowth; cannot infer negative stock return from these caveats either. Issuers benefit from favorable metrics; creditors require cash. Conditional chain1 CAN miningpressure lowersrigdemand,2 inventorywriteoffs/cashneeds triggerassetsales,3 reducedliquidity may constrainfuturecapacity; actualsectorpriceimpact unestimated. ABM/UNFI efficiency could improvefuturecash if investmentsdeliver; supplier/customerbenefits not quantified. No newedge orFUND proposal.

START49.14fundcash/850.99equity,flat,noqueue;GOALrepeatablenetpre-eventbasehits;BINDINGconstraintvalidatedneteventedge. Premises1 AVOissuerAug25Sep8afterclose https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-release-fiscal-third-quarter-2026-financial leavesonlysame-daywindow;priorT1entrySep4passed.2 Preregistered1158 baselineholdout-7.3318%N6,p50%,W1.31844/L3.74363%,training-15.6021%;all16holdoutvariantslose;quarterKelly0.3 Technical1164costedrangeRR1.1784<1.5andweeklyregimeweak; fundamental1170Calavostructuralbreakdoesnotsupplymissingedge.4 UPB1174RSSprimary https://investors.upstreambio.com/news-releases/news-release-details/upstream-bio-presents-results-phase-2-valiant-trial-verekitug explicitlyrepeatstopline;newsecondarydatadoesnotvalidateeventreturn.5 Own3losses2censored;RARE6.44Rlossdemonstrates15minstopnotgaplimit. CONCLUSION noPROPOSE/EXIT/ADJUST/FUND,retain49.14cash,noorders/stopsnecessaryflat. Validityfailednecessarygatesentailrejection; soundnesslimitsselectedissuerandfinitehistory,archivaldateavailability,dailyfillmodelandactualfeesunknown. Strongcounterargumentnewmergerregimeorsecondaryclinicaldetailcoulddrivegains;theseareunestimated,notnetodds. Evidence to revise: independentlypreregisterednotice-awareeventcohortwithpositivecost-stressedmeanCI,matchedregime,currentpre-eventwindow,freshvenuequotesandgap-aware<=8.5099risk; favorableearningsalonechangeswatchnotallocation. Monthly349.01shortfallcannotaffectp/W/L. Calendar1176/handoff1032coversnext2sessions;5activejobsand20monitorsretained;newAVOmonitor422unarmed,job52alreadyreminds. Nootherfundmonitorresolved. Finished~15minutes,within39planned/45max;last5minutesjournaling/report. NamedgapsUPBposter/widerFDAuniverse/AVOarchiveand15minfills;noextratestingafterfailededge.

PrimarysourceURLs individuallyrecordedthisruninobservations15013–15237 and15679;earliercalendar663nowrevalidated. Sep8 beforeopen:ABM08:30ETcall https://abm.gcs-web.com/news-releases/news-release-details/abm-announce-third-quarter-2026-financial-results ;UNFImorning08:30ETcall https://ir.unfi.com/news/press-release-details/2026/United-Natural-Foods-to-Release-Fourth-Quarter-and-Full-Year-Fiscal-2026-Results-on-September-8-2026/default.aspx ;CAN08ETcall https://investor.canaan-creative.com/news-releases/news-release-details/canaan-inc-report-second-quarter-2026-financial-results . ROIV06:15ETpresentation/08ETcall https://investor.roivant.com/news-releases/news-release-details/roivant-present-topline-results-phase-2-phocus-study-mosliciguat ;INBX08ETclinicalcall inobs15117. No regularsessionrunupremains. Sep8aftercloseAVO17ETcall,BRZE16:30ETcall,CASYnextday08:30ETcall;GMEexpectscompleteSep8dateonlyafterAug31preliminary. SourceCASYPDFaccessnowworks https://investor.caseys.com/node/17571/pdf . Sep9beforeopenCHWY08ETcall,ASO10ETcall;TYRA/IRD08ETclinicalcalls;ITX.MCH1dateonly https://www.inditex.com/itxcomweb/es/en/investors/finance . Calltimesnotfirstnewstimestamps; noverifiedsame-dayrunupedge. FDAnoSep8/9meetingidentifiedinretrievedcalendar https://www.fda.gov/advisory-committees/advisory-committee-calendar ;notexhaustivePDUFAcoverage. TLXSep11goal https://telixpharma.com/news-views/fda-accepts-nda-for-tlx101-px-pixclara/ ;earlydecisionpossible. MACROSep8QFR10ET https://www.census.gov/economic-indicators/calendar-listview.html ;SCE11ET https://www.newyorkfed.org/research/calendars/i-sep26.html ;ConsumerCredit15ET https://www.federalreserve.gov/newsevents/2026-september.htm . Sep9JuneECEC/Q2QSS10ET https://www.bls.gov/schedule/2026/ andCensus;STE Odateonly https://www.eia.gov/outlooks/steo/outlook.php . PPI/CPIareSep10/11. ACTIONSnext12:30UTCcheckearliestprimaryclinical/earningsreleases,fullendpointpopulation+safetyandoperatingcash. Favorablecredibleincrementalevidencechangeswatchonly;requiresindependentnetedgebeforeanyorder. Adverse/delayed/unclear -> staycash,reverifydate;nopresumptiondelayfromchosenreviewtime. Existing20monitors/5jobs coverrecordedselecteduniverse;AVOnewmonitor422capUNARMED,existingjob52reminderretained. NoCatalystduemonitors;donotresolveotherfunds'. No queuedorder/stopsneededflat.

Premises1 Sep8issuer https://investors.upstreambio.com/news-releases/news-release-details/upstream-bio-presents-results-phase-2-valiant-trial-verekitug publishedRSS07:30:11UTC,fullpage200,explicitlypreviouslyreported56%AAERreduction,N478,100mgq12w. Feb11 https://investors.upstreambio.com/news-releases/news-release-details/upstream-bio-reports-positive-top-line-results-phase-2-valiant p<.0003 vsSep8p<.001areconsistentthresholds,notcontradictorynewp.2 Sep1 https://investors.upstreambio.com/news-releases/news-release-details/upstream-bio-announces-pivotal-phase-3-development-plans plans400mgq12w,~1500across2pivotaltrials,Q12027initiation,possible2030launchconditional. Do notconfuse100mgobservedoutcomewith400mgphase3outcome.3 Aug11cash261.3m/netloss39.7m,issuer runwaythrough2027; trials/launchlaterrequirefundingassessmentnotcurrentapprovalvaluation. Conclusionno pre-toplinerunupremains;newsecondaryanalysesmaybeclinicallyusefulbutnocostedpostpresentationedge. NewsourcecamefromRSSafterstaleindex;fullposter/safetydenominatorcomparisoncutatdiscoveryallowance,notassertnoincrementalinformation. Benefitclaimssponsorbiased;repeatcitationssameorigin. Conditionalchain1 differentiateddosingreplicates;2 adequatelyfundedtrialsregulatorysuccess;3 commercialadoptioncouldbenefitUPB,competitorsfacepressure;eachlinkunprovenforpricedreturn.

Factsdatedinobservations: CensusSep8QFR10ET/Sep9QSS10ET https://www.census.gov/economic-indicators/calendar-listview.html ; NYFedSep8SCE11ET https://www.newyorkfed.org/research/calendars/i-sep26.html ;BLSJuneECECSep9 10ET https://www.bls.gov/schedule/2026/ ;AVOJun8https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-second-quarter-financial/ . ConditionalchainA1 genuineharvestnormalizationandCalavoutilizationraiseperunitmargins;2 workingcapitalreleaseandnetcashsynergiesfunddebtservice;3 lessfundingneedcouldbenefitAVOequityandgrowerpaymentreliability. NegativeA1 integration/coresizemismatcherodesmargins;2 inventoryandinterestabsorbprofit;3 debtconstraintlimitsbuybacksandgrowercontractflexibility. ChainB1 higherexpectedinflation/laborcosts;2 consumeraffordabilityandretail/servicecustomerbudgetsweaken;3 CHWY/ASOdiscretionarymixandBRZEcustomerexpansioncouldslow,valuationsalsoaffected. Benigncostswithstrongservicescanreversechain; macroaggregatescannotproveissuerfundamentals. Who benefits:customersmaygainfromlowerfruitpriceswhileAVOmarginfalls;managementadjustedmetricsneedGAAPcashcrosscheck. Conclusionwatchactualreleaseandfirmcash,zeropriceprobabilityinferred; noautomaticorder.

PrimaryJune8issuer https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-second-quarter-financial/ . Premises1 Q2volume+15%butprice-36%,revenue290.9m,GM7%,EBITDA7.1vs19.1m=-62.8272%. Scarcecoresizesanddelayedharvestcanhurtdistributormargindespiteoverallfruitabundance.2 H1CFO-21m-capex22.9m=FCF-43.9m,seasonal;cannotextrapolateyear.3 CalavoclosedMay28,266mcashplus17.530823mshares;combined88.3mshares,350mtermloans. Sep4price12.68givesproxycap1119.644m,mixedvintage;postdeal cashunverified,noEVclaim.4 Q3EBITDA28–32m,H284–88mimpliesmidQ456m;synergy25+m beginsQ4andrelatedexpensesaddedback. Conclusionrevieworganicperunitmargin,workingcapitalandrealizedcashsynergies;acquisitionrevenueisnotorganicgrowthorreturns. CounterexampleQ4harvestrecoverymaygeneratecash;confirmsbusinesspotentialnotvalidatedpre-eventedge. Issuerbenefitsfromemphasizingsynergies;priorholdersbeardilutionandlendersrequirecash. No tradeevenifguideconfirmedwithoutindependentnetrule.

Premises1 sample16trainingT1barrieroutcomes from1158; resampleiid100000paths20events,seed2026090808; preservecompleteeventreturnincludingcosts.2 Starting49.14,f25%bookmedian45.7793,p05/9544.0633/47.6608,lossprob99.787%;f100%median36.8356,p05/9531.5654/43.3056,lossprob99.818%,probDD20=81.486%.f0retains49.14beforeexternalcosts.3 EmpiricalexitdistributiontrainingN16target0%,stop25%,time75%; one-session1.5ATRtargethistoricallynotachievedintraining.4 Trainingedgep12.5%,W2.92334%,L2.01729% => clippedquarterKelly0. Conclusionadoptzero;quarter-bookscenarioisnotquarterKellyrecommendation. CounterargumentMonteCarlotaildependsheavilyon16selectedoldregimeeventsandIIDassumption; simulationaddsnoindependentobservationsandcannotcaptureunseenearlynews/mergerregime. 20eventsnot23days, nofalsemonthlyforecast. Sources https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=AVO ;primarydatedcorpusrecorded; scriptresearch/test.py. Fees10bpslip10bpeachside,sweepsnotoptimized.

Premises1 fixedT1barrier10bpfee+10bpslip study1158 useslaggedprice>SMA50,mom20>0,SPY>SMA200; nooptimizedthresholds.2 TrainingjointtrueN9mean-1.18342%,p11.111%;holdoutjointtrueN3mean-.509099%,p66.667%,W.852104%,L3.23150%,CI[-3.23150,.906283]%.3 Allobservedtrend/momentum/SPYfilterstateshavenegativemean;holdoutSPYfalseN0notmeasuredzero. Conclusionnegativeexpectancyacrosssmallcells; winrate66.7%cannotjustifyentry. Correlations/filtersnotindependentcorroborationusingthesame22events. CurrentAVOtrendandmomentumbothnegative. Source https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=AVO,SPY ;allcellsobservations15318–15339.

SIPadjusteddailybars throughSep4only https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=AVO,UPB&timeframe=1Day&feed=sip&adjustment=all . Premise1 AVOclose12.68<SMA5012.8794,mom20-3.9394%,ATR14simpleTR.344279,meanrange20.323495,low20 12.33/high20 13.64,vol20annual21.3615%,medianvolume460854.5;3sharesaffordable.2 UPB6.01<SMA506.9261,mom20-17.1034%,ATR.4783,range.44981,vol71.8380%,medianvolume561606;8sharesaffordable.3 Illustrativestop1ATR,target1.5ATR producesAVO12.33572/13.19642 andUPB5.5317/6.72745,netRR1.17843/1.38013 after10bpfee+10bpslipeachside<1.5. Noactualordersorexecutablequotes. Conclusionreject; do notwidentargettogameRR. Whole-lotaffordabilitydoesnotsupplyedge. Worsthistoryopen-closepriorgapAVO-16.7166%,UPB-31.6793%;stopisnotguaranteedfill. Dailyaggregateandadjustedhistorylimitationsprevent15minexitauthorization.

Premise1 query_tradesfundcatalyst3closedalllosses,meanloss16.3806%,total-31.937258;2operatorliquidationscensorplannedexits.0/3doesnotprovep0:IIDbinomialone-sided95%upper63.1597%,butheterogeneoussampleinvalidatesusingitascalibration;avgwinunknown. Premise2 frozenAVOT1time trainN16mean-1.03766%,holdoutN6mean-1.21259%,bootstrapCI[-3.75774,1.05684]%;medianholdout+.01312%doesnotoffsetlosstail. Premise3 OLST1netreturnonmatchingSPYopen-close:trainalpha-1.03893%,beta.01461,R2.0000647;holdoutalpha-.614015%,beta1.07551,R2.098246,N6too smallcausalinference. Conclusion no measurablepositiveedge;clippedquarterKelly0. Counterexampletruenewpostmergeredgecoulddiffer,requiresprospectivedatainsteadretuning. Sources runway:query_trades?fund=catalyst ; https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=AVO,SPY&timeframe=1Day&feed=sip&adjustment=all . EventprimaryURLsobservations152xx;sampleisoneissuersurvivorselectedfortodaydate,notuniverseestimate.